Evidence map›Paper›PMID 32908170›Full record

ArticleScientific reports2020

Discovery of a selective, state-independent inhibitor of Na

H Pajouhesh, J T Beckley, A Delwig, H S Hajare, G Luu, D Monteleone, X Zhou, J Ligutti, S Amagasu, B D Moyer and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Saxiphilin is a broad-spectrum toxin sponge for C13-modified saxitoxins.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. The Chemistry and Biology of the Tetrodotoxin Natural Product Family.Angewandte Chemie (International ed. in English) · 2025
    Review
  8. Review
  9. Role of NaThe Journal of physiology · 2024
    Article
  10. Review
  11. Article
  12. Structure of human NaNature communications · 2023
    Article
  13. Article
  14. Article
  15. Discovery of Selective Inhibitors of NaACS medicinal chemistry letters · 2022
    Article
  16. Review
  17. Article
  18. Role of NaBritish journal of pharmacology · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

H Pajouhesh *SiteOne Therapeutics, South San Francisco, CA, 94080, USA.
J T Beckley *SiteOne Therapeutics, Bozeman, MT, 59715, USA.
A Delwig *SiteOne Therapeutics, South San Francisco, CA, 94080, USA.
H S HajareDepartment of Chemistry, Stanford University, Stanford, CA, 94305, USA.
G LuuSiteOne Therapeutics, South San Francisco, CA, 94080, USA.
D MonteleoneSiteOne Therapeutics, South San Francisco, CA, 94080, USA.
X ZhouSiteOne Therapeutics, South San Francisco, CA, 94080, USA.
J LiguttiNeuroscience Department, Amgen Research, Thousand Oaks, CA, 91320, USA.
S AmagasuNeuroscience Department, Amgen Research, Thousand Oaks, CA, 91320, USA.
B D MoyerNeuroscience Department, Amgen Research, Thousand Oaks, CA, 91320, USA.
D C YeomansDepartment of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA, 94305, USA.
J Du BoisDepartment of Chemistry, Stanford University, Stanford, CA, 94305, USA.
J V MulcahySiteOne Therapeutics, South San Francisco, CA, 94080, USA. john.mulcahy@site1therapeutics.com.
SiteOne Therapeutics (United States) · USAmgen (United States) · USStanford University · US

Funding

Guanidinium Toxins as Molecular Probes for NaV StudyR01GM117263 · NIGMS · STANFORD UNIVERSITY · PI DU BOIS, JUSTIN · 2016 to 2024
$3.5M
Development of Selective Inhibitors of NaV1.7 as Therapeutics for PainR44NS081887 · NINDS · SITEONE THERAPEUTICS, INC. · PI DELWIG, ANTON, MULCAHY, JOHN VINCENT · 2014 to 2017
$2.9M
Design, Synthesis and Evaluation of Novel Isoform-Selective Sodium Channel InhibiR43NS081887 · NINDS · SITEONE THERAPEUTICS, INC. · PI MILJANICH, GEORGE, MULCAHY, JOHN VINCENT · 2013 to 2013
$236k
NIGMS NIH HHS R01 GM117263NIH HHS R01 GM117263-01A1NINDS NIH HHS R43 NS081887NINDS NIH HHS R44 NS081887
6 · The paper itself

Abstract

The voltage-gated sodium channel isoform Na

Indexed as

AnimalsDrug DiscoveryGanglia, SpinalGuanidineHumansNAV1.1 Voltage-Gated Sodium ChannelNAV1.2 Voltage-Gated Sodium ChannelNAV1.3 Voltage-Gated Sodium ChannelNAV1.4 Voltage-Gated Sodium ChannelNAV1.5 Voltage-Gated Sodium ChannelNAV1.6 Voltage-Gated Sodium ChannelNAV1.7 Voltage-Gated Sodium ChannelNAV1.8 Voltage-Gated Sodium ChannelProtein Structure, SecondarySodium Channel BlockersGuanidineNAV1.1 Voltage-Gated Sodium ChannelNAV1.2 Voltage-Gated Sodium ChannelNAV1.3 Voltage-Gated Sodium ChannelNAV1.4 Voltage-Gated Sodium ChannelNAV1.5 Voltage-Gated Sodium ChannelNAV1.6 Voltage-Gated Sodium ChannelNAV1.7 Voltage-Gated Sodium ChannelNAV1.8 Voltage-Gated Sodium ChannelSodium Channel Blockers

Identifiers

PMID32908170
PMCPMC7481244
OpenAlexW3084195837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.